Immune-Mediated Thrombocytopenia

Immune-mediated thrombocytopenia (ITP) is an acquired hematologic disorder characterized by accelerated destruction of platelets mediated by the immune system, leading to thrombocytopenia and a variable risk of bleeding. In veterinary medicine, ITP is most commonly recognized in dogs, with a similar but less frequent occurrence in cats. The disease can be classified as primary (idiopathic) or secondary, depending on the presence of an underlying trigger. Primary ITP is an immune dysregulation syndrome where autoantibodies target platelet surface glycoproteins, while secondary ITP arises from identifiable causes such as infections, neoplasia, or drug administration. The clinical spectrum ranges from subclinical thrombocytopenia to severe, life-threatening hemorrhage. The pathophysiology involves both humoral and cell-mediated immune responses, with the spleen and liver playing key roles in platelet sequestration and destruction. The diagnosis requires a thorough exclusion of other causes of thrombocytopenia, and treatment typically involves immunosuppressive therapy and supportive care. The prognosis is generally favorable with prompt and appropriate management, but complications such as intracranial hemorrhage or thromboembolism can be fatal.

The etiology of ITP is multifactorial. Primary (idiopathic) ITP is believed to result from a breakdown in immune tolerance, leading to the production of autoantibodies against platelet membrane glycoproteins, particularly GPIIb/IIIa. The inciting cause is often unknown, but may involve molecular mimicry, polyclonal B-cell activation, or defective T-regulatory cell function. Secondary ITP can be triggered by various infectious agents, including Ehrlichia canis, Anaplasma platys, Babesia canis, Leishmania infantum, and viral infections such as canine distemper virus. Neoplastic conditions, especially lymphoproliferative disorders, can induce ITP through immune dysregulation. Drug-induced ITP has been associated with certain antibiotics (e.g., sulfonamides, penicillins), non-steroidal anti-inflammatory drugs, and chemotherapeutic agents. Vaccination has been implicated in some cases, though the causal link remains controversial. Other potential triggers include blood transfusions, pregnancy, and systemic inflammatory conditions. The exact molecular mechanisms involve the binding of autoantibodies to platelet antigens, leading to Fc receptor-mediated phagocytosis by macrophages in the spleen and liver, as well as complement-mediated lysis. Additionally, cytotoxic T cells may directly destroy platelets and megakaryocytes, contributing to decreased platelet production.

ITP is most commonly diagnosed in dogs, with a reported incidence of approximately 0.2% to 0.4% of the canine hospital population. It can affect any breed, but certain breeds appear to be predisposed, including Cocker Spaniels, Poodles, Old English Sheepdogs, and German Shepherds. Female dogs may be slightly overrepresented. The age of onset is typically middle-aged, with a median age of 6 to 8 years, though it can occur in younger animals. In cats, ITP is less common, with no strong breed or sex predilection, and it often occurs secondary to underlying diseases such as feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection. Geographic variations reflect the prevalence of infectious triggers; for example, in regions where ehrlichiosis is endemic, secondary ITP is more frequent. Seasonal patterns may correlate with vector activity. The disease is sporadic, with no clear environmental risk factors beyond exposure to infectious agents or drugs.

The pathophysiology of ITP involves a complex interplay between the innate and adaptive immune systems. In primary ITP, autoreactive B cells produce antibodies against platelet surface glycoproteins, particularly GPIIb/IIIa and GPIb/IX. These antibodies bind to platelets, opsonizing them for phagocytosis by macrophages expressing Fc gamma receptors in the spleen and liver. The spleen is the primary site of platelet destruction, but the liver can also contribute, especially in severe cases. Complement activation may also lead to direct lysis of platelets. In addition to peripheral destruction, there is evidence of impaired thrombopoiesis; autoantibodies can bind to megakaryocytes, leading to reduced platelet production. T-cell dysregulation, including decreased regulatory T cells and increased cytotoxic T cells, contributes to the autoimmune process. In secondary ITP, the immune response is triggered by molecular mimicry, where antibodies directed against infectious agents cross-react with platelet antigens, or by immune complex deposition on platelets. The resulting thrombocytopenia leads to a bleeding tendency, but the severity of bleeding is not directly correlated with platelet count; rather, it depends on platelet function and vascular integrity. Chronic ITP may lead to bone marrow hyperplasia in response to increased platelet destruction, but in some cases, marrow suppression can occur.

Predisposing factors for ITP include genetic susceptibility, as certain breeds have a higher incidence, suggesting a hereditary component. Underlying infections, particularly vector-borne diseases, are significant risk factors in endemic areas. Immunosuppression, whether due to concurrent disease or drug therapy, may increase the risk of developing ITP. Certain medications, such as sulfonamides and penicillins, have been implicated as triggers. Vaccination has been proposed as a potential trigger, though the evidence is not definitive. Age and sex may also play a role, with middle-aged female dogs being at higher risk. Stress and concurrent inflammatory conditions may exacerbate immune dysregulation. Environmental factors, such as exposure to toxins or poor nutrition, are less well-defined but may contribute to immune dysfunction.

The clinical signs of ITP are primarily related to thrombocytopenia and the resulting bleeding tendency. The onset can be acute or chronic. In peracute cases, animals may present with sudden severe hemorrhage, collapse, or even death. Common clinical signs include petechiae and ecchymoses on the skin and mucous membranes, epistaxis, hematuria, melena, hematochezia, and bleeding from the gingiva. In severe cases, hematemesis, hemoptysis, or intracranial hemorrhage may occur, leading to neurological signs such as seizures, ataxia, or altered mentation. Physical examination may reveal pale mucous membranes due to blood loss, tachycardia, and weak pulses. Fever may be present if there is an underlying infection or inflammation. Splenomegaly may be palpable in some cases. In chronic cases, signs may be more insidious, with intermittent bleeding episodes and lethargy. It is important to note that the severity of bleeding does not always correlate with the platelet count; some animals with very low platelet counts may have minimal bleeding, while others with moderate thrombocytopenia may have significant hemorrhage.

The differential diagnoses for ITP include other causes of thrombocytopenia, such as decreased platelet production due to bone marrow disorders (e.g., aplastic anemia, myelodysplasia, leukemia), increased platelet consumption or sequestration (e.g., disseminated intravascular coagulation, vasculitis, splenic sequestration), and drug-induced thrombocytopenia. Infectious diseases that can cause thrombocytopenia include ehrlichiosis, anaplasmosis, babesiosis, leptospirosis, and feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infections. Neoplastic conditions, particularly lymphosarcoma and hemangiosarcoma, can also lead to thrombocytopenia. Other immune-mediated diseases, such as systemic lupus erythematosus (SLE), may present with thrombocytopenia. Additionally, platelet clumping due to improper blood collection can cause pseudothrombocytopenia. Key differentiating features include the presence of other cytopenias, bone marrow examination findings, serological or PCR testing for infectious agents, and response to therapy. For example, in ehrlichiosis, there may be concurrent leukopenia and hyperglobulinemia, and the animal may respond to doxycycline. In bone marrow disorders, the marrow is hypocellular or infiltrated with neoplastic cells. Drug-induced thrombocytopenia typically resolves after withdrawal of the offending drug.

The diagnostic algorithm for ITP begins with a thorough history and physical examination, with particular attention to bleeding signs and potential triggers. A complete blood count (CBC) is essential to confirm thrombocytopenia and to assess other cell lines. A blood smear should be examined to rule out platelet clumping and to evaluate platelet morphology. If thrombocytopenia is confirmed, the next step is to rule out infectious causes, especially in endemic areas, using serology or PCR for Ehrlichia, Anaplasma, Babesia, and other pathogens. A chemistry panel and urinalysis are performed to assess organ function and to detect underlying diseases. If no underlying cause is identified, a bone marrow aspirate or biopsy may be indicated to evaluate megakaryocyte numbers and to rule out primary bone marrow disorders. In primary ITP, the bone marrow typically shows increased or normal numbers of megakaryocytes. Additional tests, such as anti-platelet antibody assays, may be performed, but their sensitivity and specificity are variable, and they are not always necessary for diagnosis. The diagnosis of ITP is often made by exclusion, based on the presence of severe thrombocytopenia, normal or increased megakaryocytes in the bone marrow, and the absence of other identifiable causes. Response to immunosuppressive therapy can also support the diagnosis.

The hallmark laboratory finding in ITP is a severe thrombocytopenia, often with platelet counts below 30,000/µL. The CBC may also show mild anemia due to blood loss, and in chronic cases, iron deficiency may develop. Leukocyte counts are usually normal or mildly elevated, but may be decreased if there is concurrent infection or bone marrow suppression. A blood smear is critical to rule out platelet clumping, which can cause pseudothrombocytopenia. Platelet morphology may show large platelets (megathrombocytes) indicating increased turnover. Serum biochemistry is typically unremarkable, but may reveal hypoalbuminemia due to blood loss, or elevated liver enzymes if there is concurrent disease. Urinalysis may show hematuria. Coagulation testing, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), is usually normal in ITP, helping to differentiate it from DIC. Specific biomarkers, such as anti-platelet antibodies, can be measured using flow cytometry or ELISA, but their diagnostic utility is limited. In secondary ITP, serological or PCR testing for infectious agents may be positive. Bone marrow examination typically shows normal or increased numbers of megakaryocytes, with no evidence of neoplastic infiltration.

Imaging studies are not typically used for the diagnosis of ITP, but they may be helpful in identifying underlying causes or complications. Thoracic radiographs may be performed to evaluate for metastatic disease or pneumonia if an infectious etiology is suspected. Abdominal ultrasonography can assess for splenomegaly, lymphadenopathy, or abdominal masses that may indicate neoplasia. In cases of suspected intracranial hemorrhage, advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) may be indicated, but these are rarely performed due to the critical condition of the patient. Echocardiography may be considered if there is suspicion of infective endocarditis, which can cause thrombocytopenia. Overall, imaging is of limited value in the routine diagnosis of ITP, but it can be useful in the diagnostic workup for secondary causes.

Cytological examination of bone marrow aspirates is a key diagnostic tool in ITP. The bone marrow typically shows normal or increased numbers of megakaryocytes, with a shift towards younger forms, indicating increased platelet production. There may be evidence of erythroid hyperplasia if there is concurrent blood loss. In secondary ITP, the marrow may show changes related to the underlying disease, such as neoplastic infiltration in lymphoma. Histopathological examination of bone marrow biopsies can provide more detailed information about cellularity and architecture. In some cases, splenic aspirates or biopsies may be performed if splenomegaly is present, but this is not routine. The presence of anti-platelet antibodies can be demonstrated using immunocytochemistry, but this is not widely available. Overall, cytology and histopathology are important to rule out primary bone marrow disorders and to support the diagnosis of ITP.

The treatment of ITP aims to rapidly increase platelet counts and prevent life-threatening bleeding. The cornerstone of therapy is immunosuppression with corticosteroids, such as prednisone or prednisolone, at a dosage of 1-2 mg/kg PO q12h. In severe cases, pulse therapy with methylprednisolone sodium succinate (10-30 mg/kg IV) may be used. If there is no response to corticosteroids within 48-72 hours, or if the animal is critically ill, additional immunosuppressive agents may be added, such as vincristine (0.02 mg/kg IV once), cyclosporine (5-10 mg/kg PO q12h), azathioprine (2 mg/kg PO q24h), or mycophenolate mofetil (10 mg/kg PO q12h). Human intravenous immunoglobulin (hIVIG) can be used at a dose of 0.5-1 g/kg IV over 6-12 hours, which can rapidly increase platelet counts by blocking Fc receptors. In cases of severe, life-threatening hemorrhage, platelet-rich plasma or whole blood transfusions may be administered, although their efficacy is limited due to rapid destruction of transfused platelets. Supportive care includes fluid therapy, blood pressure management, and gastrointestinal protectants if corticosteroids are used. Splenectomy is rarely performed in veterinary medicine but may be considered in refractory cases. The treatment plan should be tailored to the individual patient, with careful monitoring for adverse effects of immunosuppressive therapy.

The prognosis for ITP is generally good, with a reported survival rate of 70-90% in dogs with appropriate treatment. The response to therapy is often rapid, with platelet counts increasing within 3-5 days. However, the disease can be fatal in severe cases, particularly if intracranial hemorrhage occurs. Negative prognostic indicators include a very low platelet count (<10,000/µL), severe bleeding at presentation, lack of response to initial therapy, and the presence of concurrent diseases. Chronic ITP may require long-term immunosuppressive therapy, and relapses can occur. The prognosis for secondary ITP depends on the underlying cause; if the trigger is successfully treated, the ITP may resolve. Overall, with prompt and aggressive treatment, the short-term prognosis is favorable, but long-term management may be necessary.

Follow-up care for ITP involves regular monitoring of platelet counts and clinical signs. Initially, platelet counts should be checked every 1-3 days until they stabilize above 50,000/µL. Once the platelet count is stable, the frequency of monitoring can be reduced to weekly, then monthly. The dose of immunosuppressive drugs should be tapered gradually over several weeks to months, based on the platelet response. For example, prednisone may be tapered by 25% every 2-4 weeks. If the animal is on multiple immunosuppressive agents, they should be tapered one at a time. Long-term monitoring should include a CBC and chemistry panel to assess for drug side effects, such as hepatotoxicity or bone marrow suppression. If the ITP was secondary to an infectious agent, repeat serology or PCR may be indicated to confirm resolution. Owners should be educated to monitor for signs of bleeding and to seek immediate veterinary care if they occur. Regular veterinary check-ups are essential to adjust therapy and to detect any relapses.

Pearls: 1) Always examine a blood smear to rule out platelet clumping, which can cause pseudothrombocytopenia. 2) In a stable patient with severe thrombocytopenia, avoid unnecessary procedures such as venipuncture or catheter placement to minimize bleeding risk. 3) Consider starting immunosuppressive therapy immediately if ITP is strongly suspected, even before all diagnostic tests are complete, as delays can be fatal. 4) Use vincristine as an adjunct in severe cases, as it can increase platelet counts within 24-48 hours. 5) Monitor for thromboembolic complications, as ITP can paradoxically increase the risk of thrombosis due to the presence of large, young platelets. Pitfalls: 1) Do not administer platelet transfusions unless there is life-threatening bleeding, as they are rapidly destroyed and can worsen the immune response. 2) Avoid the use of non-steroidal anti-inflammatory drugs (NSAIDs) in thrombocytopenic patients, as they impair platelet function. 3) Do not taper immunosuppressive therapy too quickly, as this can lead to relapse. 4) Be cautious with the use of corticosteroids in patients with concurrent infections, as they can exacerbate the infection. 5) Do not forget to screen for infectious diseases, especially in endemic areas, as treating the underlying infection may resolve the ITP without long-term immunosuppression.

The following drug protocols are based on Plumb's Veterinary Drug Handbook and current veterinary literature. Prednisone: 1-2 mg/kg PO q12h for 2-4 weeks, then taper gradually over 2-3 months. Methylprednisolone sodium succinate: 10-30 mg/kg IV once, for severe cases. Vincristine: 0.02 mg/kg IV once, can be repeated after 7 days if needed. Cyclosporine: 5-10 mg/kg PO q12h, with therapeutic drug monitoring to maintain blood levels of 400-600 ng/mL. Azathioprine: 2 mg/kg PO q24h, with dose reduction after 2-4 weeks to q48h. Mycophenolate mofetil: 10 mg/kg PO q12h. Human intravenous immunoglobulin (hIVIG): 0.5-1 g/kg IV over 6-12 hours, can be repeated if necessary. For secondary ITP, treat the underlying cause, e.g., doxycycline 5-10 mg/kg PO q12h for ehrlichiosis. Supportive care: IV fluids (e.g., lactated Ringer's solution) at maintenance rates (60-100 ml/kg/day) to correct dehydration. Gastrointestinal protectants (e.g., omeprazole 0.7-1 mg/kg PO q24h) if corticosteroids are used. All immunosuppressive drugs should be used with caution in patients with hepatic or renal impairment, and dosages may need adjustment. Drug interactions: Corticosteroids may interact with NSAIDs, increasing the risk of gastrointestinal ulceration. Cyclosporine may interact with ketoconazole, increasing its blood levels. Azathioprine should not be used with allopurinol, as it can cause severe bone marrow suppression.

Evidence-based literature on ITP in veterinary medicine is limited, but several studies have provided valuable insights. A retrospective study by Lewis et al. (2013) reported a survival rate of 85% in dogs with primary ITP treated with immunosuppressive therapy. Another study by O'Marra et al. (2011) found that the addition of vincristine to corticosteroid therapy resulted in a faster increase in platelet counts compared to corticosteroids alone. A consensus statement from the American College of Veterinary Internal Medicine (ACVIM) on the diagnosis and treatment of immune-mediated hemolytic anemia and thrombocytopenia was published in 2019, providing guidelines for diagnosis and management. The use of hIVIG has been evaluated in a small study by Bianco et al. (2009), which showed a rapid increase in platelet counts in dogs with severe ITP. However, the high cost and limited availability of hIVIG restrict its use. There is ongoing research into the role of T-cell dysregulation in ITP, and future therapies may target these pathways. Overall, the evidence supports the use of corticosteroids as the first-line treatment, with the addition of other immunosuppressive agents in refractory cases. Further studies are needed to establish optimal treatment protocols and to identify prognostic factors.